LivaNova (NASDAQ:LIVN) had its price objective boosted by Piper Sandler from $81.00 to $92.00 in a report published on Monday morning, Benzinga reports. The firm currently has an overweight rating on the stock. Piper Sandler also issued estimates for LivaNova’s Q4 2022 earnings at $0.79 EPS.
Several other research analysts also recently commented on the stock. Needham & Company LLC reaffirmed a hold rating on shares of LivaNova in a research note on Thursday, March 4th. Berenberg Bank reiterated a hold rating and set a $84.00 target price on shares of LivaNova in a report on Tuesday, March 9th. Zacks Investment Research upgraded shares of LivaNova from a sell rating to a hold rating in a report on Monday, February 15th. Finally, TheStreet raised shares of LivaNova from a d+ rating to a c- rating in a research report on Tuesday, February 23rd. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. LivaNova has a consensus rating of Hold and an average target price of $69.33.
LIVN opened at $83.15 on Monday. The firm has a market cap of $4.05 billion, a P/E ratio of -19.34 and a beta of 0.80. LivaNova has a 1-year low of $41.07 and a 1-year high of $85.17. The company has a 50 day simple moving average of $77.94 and a two-hundred day simple moving average of $65.33. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.39 and a quick ratio of 1.76.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 24th. The company reported $0.71 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.03. LivaNova had a negative net margin of 21.88% and a positive return on equity of 5.55%. The business had revenue of $269.60 million during the quarter, compared to analyst estimates of $268.83 million. During the same period in the prior year, the business posted $1.00 earnings per share. The company’s revenue was down 6.3% on a year-over-year basis. Equities analysts anticipate that LivaNova will post 0.71 earnings per share for the current year.
Several large investors have recently bought and sold shares of the company. Arlington Partners LLC purchased a new position in shares of LivaNova during the 1st quarter valued at approximately $67,000. Henry James International Management Inc. purchased a new position in shares of LivaNova during the 1st quarter valued at approximately $578,000. Louisiana State Employees Retirement System increased its holdings in shares of LivaNova by 4.1% during the 1st quarter. Louisiana State Employees Retirement System now owns 12,600 shares of the company’s stock valued at $929,000 after purchasing an additional 500 shares in the last quarter. Susquehanna International Group LLP increased its holdings in LivaNova by 5.1% in the 4th quarter. Susquehanna International Group LLP now owns 21,202 shares of the company’s stock worth $1,404,000 after acquiring an additional 1,032 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in LivaNova by 0.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 744,209 shares of the company’s stock worth $49,276,000 after acquiring an additional 1,941 shares in the last quarter. 89.10% of the stock is owned by hedge funds and other institutional investors.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
See Also: How does a 12b-1 fee affect fund performance?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.